preclinical model comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
The Transitional Government of Ethiopia (TGE) was an era established immediately after the Ethiopian People's Revolutionary Democratic Front (EPRDF) seized power from the Marxist-Leninist People's Democratic Republic of Ethiopia (PDRE) in 1991. During the transitional period, Meles Zenawi served as the president of the TGE while Tamrat Layne was prime minister. Among other major shifts in the country's political institutions, it was under the authority of the TGE that the realignment of provincial boundaries on the basis of ethnolinguistic identity occurred. The TGE was in power until 1995, when it transitioned into the reconstituted Federal Democratic Republic of Ethiopia that remains today.
Selenium forms several allotropes that interconvert with temperature changes, depending somewhat on the rate of temperature change. When prepared in chemical reactions, selenium is usually an amorphous, brick-red powder. When rapidly melted, it forms the black, vitreous form, usually sold commercially as beads. The structure of black selenium is irregular and complex and consists of polymeric rings with up to 1000 atoms per ring. Black selenium is a brittle, lustrous solid that is slightly soluble in CS2. Upon heating, it softens at 50 °C and converts to gray selenium at 180 °C; the transformation temperature is reduced by presence of halogens and amines. The red α, β, and γ forms are produced from solutions of black selenium by varying the evaporation rate of the solvent (usually CS2). They all have a relatively low, monoclinic crystal symmetry (space group 14) and contain nearly identical puckered cyclooctaselenium (Se8) rings as in sulfur. The eight atoms of a ring are not equivalent (i.e. they are not mapped one onto another by any symmetry operation), and in fact in the γ-monoclinic form, half the rings are in one configuration (and its mirror image) and half in another. The packing is most dense in the α form. In the Se8 rings, the Se–Se distance varies depending on where the pair of atoms is in the ring, but the average is 233.5 pm, and the Se–Se–Se angle is on average 105.7°. Other selenium allotropes may contain Se6 or Se7 rings.
=== Synthesis Mechanism === When viral HIV-RNA enters the cell, it is accompanied by a reverse transcriptase, an integrase, and a mature HIV-1 PR. The reverse transcriptase converts viral RNA into DNA, facilitating the integrase's role in incorporating viral genetic information with the host cell DNA. The viral DNA can either remain dormant in the nucleus or be transcribed into mRNA and translated by the host cell into the Gag-Pol polyprotein, which would then be cleaved into individual functional proteins (including a newly synthesized HIV-1 PR) by the mature HIV-1 PR.
Elena Galoppini, Italian chemist and professor at Rutgers University–Newark whose research focuses on the development of redox- and photo-active molecules to modify surfaces. Juliet Gerrard, New Zealand chemist and Prime Minister's Chief Science Advisor in the administration of Jacinda Ardern. Clare Grey, British chemist pioneering the use of nuclear magnetic resonance spectroscopy to study battery technology. Awarded the Körber European Science Prize in 2021. Professor at the University of Cambridge. Paula T. Hammond, American chemical engineer focusing on macromolecular design and synthesis of materials for drug delivery systems, particularly in relation to cancer, immunology, and immunotherapy. Professor at MIT. Jeanne Hardy, American biophysicist and chemical biologist. Known for her work in the design of allosteric binding sites and control elements into human proteases. Professor at the University of Massachusetts. Geraldine Harriman, American Organic Chemist. Developed Firsocostat. Chief Scientific Officer and co-founder of HotSpot. Rachel Haurwitz, American biochemist and structural biologist. Her work regards CRISPR based technologies, she is a cofounder of Caribou Biosciences, a genome editing and cell therapy development company. Kim Eunkyoung, South Korean materials chemist known for her work in electrochromic (EC) materials design Katja Loos, German polymer chemist working on the design, synthesis, and characterisation of novel and sustainable polymeric materials and macromolecules. Chair of the board of the Zernike Institute for Advanced Materials.
Sources: en.wikipedia.org
== Mechanism of carcinogenicity == Aflatoxin B1 is a potent genotoxic hepatocarcinogen with its exposure strongly linked to the development of hepatocellular carcinoma, liver tumors, especially given co-infection with hepatitis B virus. These effects seem to be largely mediated by mutations at guanine in codon 249 of the p53 gene, a tumor suppressing gene, and at several guanine residues in the 12th and 13th codons of the ras gene, a gene whose product controls cellular proliferation signals. Aflatoxin B1 must first be metabolized into its reactive electrophilic form, aflatoxin B1-8,9-exo-epoxide by cytochrome p450. This active form then intercalates between DNA base residues and forms adducts with guanine residues, most commonly aflatoxin B1-N7-Gua. These adducts may then rearrange or become removed from the backbone altogether, forming an apurinic site. These adducts and alterations represent lesions which, upon DNA replication, cause the insertion of a mis-matched base in the opposing strand. Up to 44% of hepatocellular carcinomas in regions with high aflatoxin exposure bear a GC → TA transversion at codon 249 of p53, a characteristic mutation seen with this toxin.
== Personal life == In 1915, Boyd Orr married Elizabeth Pearson Callum, whom he had met as a teenager in West Kilbride. They had three children: Elizabeth Joan (born 1916), Helen Anne (born 1919) and Donald Noel (1921–1942). His son was killed on active service during the Second World War.
The first national team was in the kingdom that existed between the two world wars. The Football Federation of what was then the Kingdom of Serbs, Croats and Slovenes was founded in Zagreb in 1919 under the name Jugoslavenski nogometni savez (and admitted into FIFA), and the national team played its first international game at the Summer Olympics in Antwerp in 1920. The opponent was Czechoslovakia, and the historic starting eleven that represented Kingdom of SCS on its debut were: Dragutin Vrđuka, Vjekoslav Župančić, Jaroslav Šifer, Stanko Tavčar, Slavin Cindrić, Rudolf Rupec, Dragutin Vragović, Artur Dubravčić, Emil Perška, Ivan Granec, and Jovan Ružić. They lost by a huge margin 0–7, but nonetheless got their names in the history books.
=== Metal ion complexation === With metal ions, thiolates behave as ligands to form transition metal thiolate complexes. The term mercaptan is derived from the Latin mercurium captans (capturing mercury) because the thiolate group bonds so strongly with mercury compounds. According to hard/soft acid/base (HSAB) theory, sulfur is a relatively soft (polarizable) atom. This explains the tendency of thiols to bind to soft elements and ions such as mercury, lead, or cadmium. The stability of metal thiolates parallels that of the corresponding sulfide minerals. Sodium aurothiolate is an antiarthritic drug.
Upon activation by amphetamine, TAAR1 can couple to the Gs alpha subunit and increase intracellular cAMPTooltip cyclic adenosine monophosphate production via adenylyl cyclase activation, which triggers PKA- and PKC-mediated transporter phosphorylation. When TAAR1 couples to the G13 alpha subunit, RhoA activity increases near the endoplasmic reticulum and leads to the downstream internalization of monoamine transporters; TAAR1-dependent RhoA signaling has also been shown to internalize EAAT3Tooltip excitatory amino acid transporter 3, a neuronal glutamate transporter expressed in some monoaminergic neurons. Monoamine autoreceptors (e.g., D2 short, presynaptic α2, and presynaptic 5-HT1A) have the opposite effect of TAAR1, and together these receptors provide a regulatory system for monoamines. Notably, amphetamine and trace amines possess high binding affinities for TAAR1, but not for monoamine autoreceptors. Although TAAR1 is implicated in amphetamine-induced transporter phosphorylation, the magnitude of TAAR1-mediated monoamine release in humans remains unclear. Beyond its Gs- and G13-coupled receptor-mediated effects on monoamine transporter function, TAAR1 also opens G protein-coupled inwardly rectifying potassium channels through a separate pathway, an action that reduces neuronal firing. Amphetamine is also a substrate for the vesicular monoamine transporters VMAT1 and VMAT2. Under normal conditions, VMAT2 transports cytosolic monoamines into synaptic vesicles for storage and later exocytotic release.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.